Recombinant Human FGF R3 (IIIc)

Recombinant Human FGF R3 (IIIc) offers several compelling advantages for research applications, particularly in studying fibroblast growth factor signaling, developmental biology, and cancer research.

Biological Significance and Functional Relevance

FGFR3 plays critical roles in the development and maintenance of bone and brain tissue, with important cellular functions including regulation of cell growth and division, determination of cell type, formation of blood vessels, wound healing, and embryo development. The IIIc isoform is particularly significant because it has a broad ligand spectrum, responding to FGFs 1, 2, 4, 6, 9, and 18, compared to the IIIb isoform which responds only to FGFs 1 and 9. This broader ligand specificity makes the IIIc variant especially valuable for investigating multiple signaling pathways within a single experimental system.

Research Applications

Cancer Research: The IIIc isoform has demonstrated oncogenic effects in colorectal cancer and other malignancies. Recombinant FGFR3 (IIIc) enables researchers to study tumor cell growth, migration, and the mechanisms by which FGFR3/FGF18 signaling promotes cancer progression. This makes it invaluable for developing and testing therapeutic strategies targeting this pathway.

Tissue Engineering and Wound Healing: FGF signaling through FGFR3 is essential for tissue repair processes. Recombinant FGF proteins have demonstrated efficacy in hastening the healing of skin wounds, diabetic ulcers, spinal cord damage, and bone fractures. The IIIc variant's involvement in bone development makes it particularly relevant for bone regeneration studies.

Cell Proliferation and Differentiation Studies: The protein can be used in cell viability and proliferation assays to measure dose-dependent growth stimulation and to investigate how FGFR3 signaling influences cell fate decisions.

Technical Advantages

The recombinant protein is typically produced with high purity (>95% by SDS-PAGE) and low endotoxin levels (<0.1 EU/µg), ensuring reliable and reproducible experimental results. It is commonly provided as an Fc fusion protein, which enhances stability and facilitates detection in various assays. The protein is supplied in lyophilized form and remains stable for six to twelve months when stored at -20°C to -70°C, providing convenient long-term storage and ease of use.

Experimental Flexibility

Recombinant FGFR3 (IIIc) can be employed in multiple experimental formats, including ELISA-based assays, cell proliferation assays, and neutralization studies. Its biological activity is well-characterized, with expected ED₅₀ values of 1-3 ng/ml for inhibiting FGF-dependent proliferation, allowing for precise dose-response experiments and standardized comparisons across studies.

Yes, you can use recombinant human FGFR3 (IIIc) as a standard for ELISA quantification and calibration, though there are important considerations for optimal results.

Suitability as an ELISA Standard

Recombinant FGFR3 (IIIc) proteins are appropriate for use as ELISA standards because they provide a defined, reproducible reference material with known concentration and purity. The recombinant nature of these proteins ensures batch-to-batch consistency, which is essential for reliable standard curves. Most commercial recombinant FGFR3 (IIIc) products are supplied at high purity (typically >95% by SDS-PAGE), making them suitable for quantitative applications.

Standard Curve Preparation Guidelines

When preparing your ELISA standard curve with recombinant FGFR3 (IIIc), follow these best practices:

Concentration Range: Establish your standard curve typically ranging from 0 to 1000 pg/mL, though this can extend to 3000 pg/mL if your predicted target protein concentration is extremely high.

Reconstitution: Most recombinant proteins are supplied in lyophilized form and require reconstitution. Carefully follow the lot-specific reconstitution instructions provided with your protein, as these may vary between batches.

Formulation Selection: If using the recombinant protein for ELISA standards, consider whether you need the carrier-free formulation or one with BSA, depending on your specific assay requirements.

Technical Considerations

The molecular weight and structural form of your recombinant FGFR3 (IIIc) will affect its behavior in your assay. Most commercial versions are disulfide-linked homodimers with molecular weights ranging from approximately 64.7 kDa to 128.3 kDa depending on the expression system and glycosylation status. This information is critical for accurate concentration calculations and standard curve interpretation.

Ensure your standard curve demonstrates acceptable linearity and reproducibility before applying it to unknown samples. This validation step is essential for quantitative ELISA work.

Recombinant Human FGF R3 (IIIc) has been validated in published research for several key applications, primarily as a functional decoy receptor in cell-based assays, blocking assays, and kinase assays, as well as in studies of cell proliferation, signaling, and antibody characterization.

Validated Applications in Published Research:

• Functional Assays:
  Used to assess its ability to inhibit FGF-dependent cell proliferation, particularly in fibroblast cell lines such as NR6R-3T3 and NIH3T3. The recombinant protein acts as a decoy receptor, binding FGF ligands and preventing activation of endogenous FGFR3, which is measured by reduced cell proliferation in a dose-dependent manner (ED₅₀ typically 1–3 ng/mL).

• Blocking Assays:
  Employed to block FGF signaling in vitro, demonstrating inhibition of downstream pathways such as MAPK/ERK and PLCγ in cell models. This is relevant for studying FGFR3-mediated signaling and its pathological activation in diseases like achondroplasia and cancer.

• Kinase Assays:
  Used to investigate FGFR3 kinase activity and its inhibition by recombinant extracellular domain proteins, which can help characterize ligand-receptor interactions and downstream phosphorylation events.

• Antibody Characterization:
  Recombinant FGFR3 (IIIc) is used as an antigen for selecting and validating antibodies (e.g., scFv, monoclonal antibodies) targeting the extracellular domain. These antibodies are then tested for their ability to bind FGFR3, block ligand interaction, and inhibit cell proliferation in cancer models, such as bladder carcinoma.

• Surface Plasmon Resonance (SPR):
  Utilized to quantitatively analyze binding affinities between FGFR3 (IIIc) and various FGF isoforms or therapeutic molecules (e.g., Recifercept), providing kinetic data on ligand-receptor interactions.

• Cellular Signaling Studies:
  Applied in research to dissect FGFR3-dependent signaling pathways, including effects on cell growth, differentiation, and apoptosis. Western blot and other biochemical assays are used to monitor phosphorylation of downstream effectors after FGF stimulation and FGFR3 (IIIc) inhibition.

Additional Context:

• Disease Models:
  Recombinant FGFR3 (IIIc) has been used in models of skeletal dysplasia (e.g., achondroplasia) and cancer (e.g., bladder carcinoma) to study the effects of FGFR3 signaling modulation on cell proliferation, differentiation, and therapeutic intervention.

• Cell Types:
  Validated in fibroblast cell lines (NR6R-3T3, NIH3T3), chondrocytes, and cancer cell lines (RT112 bladder carcinoma), as well as in transgenic mouse models.

• Assay Formats:
  Includes ELISA, immunofluorescence, flow cytometry, and Western blot for detection and quantification of FGFR3 (IIIc) and its functional effects.

Summary Table:

These applications are supported by multiple peer-reviewed studies and product validation data, confirming the utility of recombinant human FGFR3 (IIIc) in both basic research and translational models.

To reconstitute and prepare Recombinant Human FGF R3 (IIIc) protein for cell culture experiments, follow these best-practice steps based on manufacturer protocols and general recombinant protein handling guidelines:

1. Centrifuge the vial:
Before opening, briefly centrifuge the lyophilized protein vial to ensure all material is at the bottom.

2. Choose the reconstitution buffer:

• If the product datasheet specifies a buffer, use that buffer (commonly sterile phosphate-buffered saline (PBS), pH 7.2–7.3, or 20 mM Tris, 150 mM NaCl, pH 8.0).
• If not specified, sterile distilled water or PBS is generally suitable for most recombinant proteins.
• Avoid buffers containing calcium or magnesium unless specifically recommended.

3. Reconstitution concentration:

• Reconstitute to a final concentration of 0.1–1.0 mg/mL (for example, add 100–1000 µL buffer per 100 µg protein).
• For some protocols, a concentration of 100 µg/mL in sterile PBS is recommended.

4. Gentle mixing:

• Add the buffer slowly down the side of the vial.
• Do not vortex; gently pipette up and down or swirl to dissolve.
• Let the solution sit at room temperature for 1–5 minutes to ensure complete dissolution.

5. Remove precipitate (if present):

• If any precipitate forms, centrifuge at 16,000 × g for 1 minute and transfer the supernatant to a new tube.

6. Aliquot and storage:

• Aliquot the reconstituted protein to avoid repeated freeze-thaw cycles.
• Store at 2–8°C for up to 1 month or at –20°C to –70°C for longer-term storage.
• Avoid frost-free freezers and repeated freeze-thawing, as this can denature the protein.

7. Working solution for cell culture:

• For cell culture, further dilute the stock in cell culture medium or buffer containing a carrier protein (e.g., 0.1% BSA) to minimize adsorption and stabilize the protein.
• Filter sterilize if necessary (0.2 µm filter) before adding to cells.

8. Typical working concentrations:

• Biological activity is often observed at 1–10 ng/mL in cell-based assays, but optimal concentrations should be determined empirically for your specific application.

Summary Table: Reconstitution and Preparation

Note: Always consult the specific product datasheet or Certificate of Analysis for lot-specific instructions, as formulations and recommended buffers may vary between suppliers.